The object of the present invention is to prepare a cancer therapeutic agent by means of a novel monoclonal antibody which binds to SLC6A6 or its extracellular region and a substance which suppresses SLC6A6 expression.The present invention provides a pharmaceutical composition comprising a monoclonal antibody which recognizes native SLC6A6 or a polypeptide in the extracellular region of SLC6A6.